

SCIENTIFIC PROGRAM

FRIDAY MARCH 4

08:00 Registration of participants

SESSION 1

08:30 – 10:30 HCV and Covid
Chairs: Petr Urbanek, Robert Flisiak

25 min HCV Clinical Practice Guidelines: The Course towards Desired Goal
Urbanek P. (Czech Republic)

20 min HCV elimination in Central Europe with particular emphasis on microelimination in prisons
Flisiak R. (Poland)
Zarębska-Michaluk D., Ciupkeviciene E., Drazilova S.,
Frankova S., Grgurevic I., Hunyady B., Jarcuska P.,
Kupcinskas L., Makara M., Saulite-Vanaga G.,
Simonova M., Sperl J., Tolmane I., Vince A.

25 min Can we eliminate hepatitis B in Slovakia?
Jarcuska P. (Slovakia)

20 min Pangenotypic and genotype-specific antivirals in the treatment of HCV Genotype 4 infected patients with HCV monoinfection and HIV/HCV coinfection
Zarębska-Michaluk D. (Poland)
Jaroszewicz J., Parfieniuk-Kowerda A., Pawłowska M.,
Janczewska E., Berak H., Janocha-Litwin J., Klapaczyński J.,
Tomasiewicz K., Piekarska A., Krygier R., Citko J.,
Tronina O., Dobrowolska K., Flisiak R.

20 min Liver injury in patients with covid-19 with liver disease and without underlying liver diseases
Pazgan-Simon M. (Poland)
Kucharska M., Simon K.

SCIENTIFIC PROGRAM

10:30 – 11:00 **Coffee Break**

SESSION 2

11:00 – 12:30	HCV and Liver Tumours Chairs: Peter Jarcuska, Sona Frankova
15 min	Safety and efficacy of DAA-therapy in patients with active malignancy Blaszkowska M. (Poland) Jaroszewicz J.
20 min	Hepatitis C viraemic donors in solid organ transplantation Frankova S. (Czech Republic)
15 min	Steatosis after clearance of HCV infection and inflammatory response Tomasiewicz K. (Poland)
10 min	Obesity after clearance of HCV infection Pitova V. (Czech Republic) Frankova S., Sperl J.
15 min	Prognostic factors of hepatocellular cancer - analysis of Slovak cohort Drazilova S. (Slovakia)
15 min	Neuroendocrine tumours and liver transplantation Filipek-Kanizaj T. (Croatia)

12:30 – 13:45 **Lunch**

SESSION 3

13:45 – 15:30	Liver Cirrhosis and Rare Liver Diseases Chairs: Radan Bruha, Ivica Grgurevic
20 min	Wilson's disease - diagnosis and treatment Bruha R. (Czech Republic)

SCIENTIFIC PROGRAM

15 min	Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography Grgurevic I. (Croatia)
15 min	Time-to a tertiary care and mortality of acutely decompensated cirrhosis Skladany L. (Slovakia) Zilincanova D., Adamcova Selcanova S.
20 min	Predictive value of sarcopenia and myosteatosis in cirrhotic patients Trunecka P. (Czech Republik) Kyselova D., Mikova I.
20 min	Preventive measures in NAFLD: can we stop the trends? Kukla M. (Poland)
15 min	Does HVPG predict response to Fecal Microbial Transplantation in severe alcoholic hepatitis? Bystrianska N. (Slovakia) Skladany L.

15:30 – 16:00 Coffee Break

SESSION 4

16:00 – 17:30	Rare Liver Diseases Pavel Strnad, Jan Sperl
25 min	Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder Strnad P. (Germany)
25 min	Autoimmune hepatitis - Challenges of diagnostic and treatment Papp M. (Hungary)
25 min	New approaches in treatment of severe unconjugated hyperbilirubinemia Vitek L. (Czech Republik)